YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Distribution of the Prevalence of Human Leukocyte Antigen (hla)-B*57:01 Positivity in Hiv-1 Infected Individuals and Its Effects on Treatment: Türkiye Map-Buhasder Working Group

dc.authorid Sarikaya, Burak/0000-0002-0026-1927
dc.authorscopusid 36179346000
dc.authorscopusid 57213591894
dc.authorscopusid 57193715608
dc.authorscopusid 57210987866
dc.authorscopusid 35783491600
dc.authorscopusid 8050689600
dc.authorscopusid 57222510645
dc.authorwosid Alkan, Sevil/Abh-8663-2020
dc.authorwosid Inan, Dilara/C-4811-2016
dc.authorwosid Tahmaz, Alper/Jbi-6530-2023
dc.authorwosid Baran, Ali/Lnr-6591-2024
dc.authorwosid Senbayrak, Seniha/Aac-4284-2019
dc.authorwosid Çelik Ekinci, Semiha/Hph-6509-2023
dc.authorwosid Sarikaya, Burak/Kfc-0092-2024
dc.contributor.author Buyuktuna, Seyit Ali
dc.contributor.author Oksuz, Caner
dc.contributor.author Tahmaz, Alper
dc.contributor.author Sarigul Yildirim, Figen
dc.contributor.author Turken, Melda
dc.contributor.author Gunal, Ozgur
dc.contributor.author Kose, Sukran
dc.date.accessioned 2025-05-10T17:42:04Z
dc.date.available 2025-05-10T17:42:04Z
dc.date.issued 2024
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp [Buyuktuna, Seyit Ali] Sivas Cumhuriyet Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Sivas, Turkiye; [Oksuz, Caner] Sivas State Hosp, Clin Infect Dis & Clin Microbiol, Sivas, Turkiye; [Tahmaz, Alper] Univ Hlth Sci, Antalya Training & Res Hosp, Clin Infect Dis & Clin Microbiol, Antalya, Turkiye; [Sarigul Yildirim, Figen] Antalya Life Hosp, Clin Infect Dis & Clin Microbiol, Antalya, Turkiye; [Turken, Melda] Univ Hlth Sci, Izmir City Hosp, Clin Infect Dis & Clin Microbiol, Izmir Fac Med, Izmir, Turkiye; [Gunal, Ozgur; Topal, Seyma] Samsun Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Samsun, Turkiye; [Baran, Ali Irfan] Van Yuzuncu Yil Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Van, Turkiye; [Sarikaya, Burak] Univ Hlth Sci, Sultan Abdulhamid Khan Training & Res Hosp 2, Clin Infect Dis & Clin Microbiol, Istanbul, Turkiye; [Celik Ekinci, Semiha] Univ Hlth Sci, Fatih Sultan Mehmet Training & Res Hosp, Clin Infect Dis & Clin Microbiol, Istanbul, Turkiye; [Kaya, Selcuk; Alkan Ceviker, Sevil] Canakkale Onsekiz Mart Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Canakkale, Turkiye; [Aypak, Adalet; Yuruk Atasoy, Pinar] Univ Hlth Sci, Ankara City Hosp, Clin Infect Dis & Clin Microbiol, Ankara, Turkiye; [Inan, Dilara] Akdeniz Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Antalya, Turkiye; [Kose, Adem] Inonu Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Malatya, Turkiye; [Koc Ince, Nevin] Duzce Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Duzce, Turkiye; [Senbayrak, Seniha] Univ Hlth Sci, Haydarpasa Numune Training & Res Hosp, Clin Infect Dis & Clin Microbiol, Istanbul, Turkiye; [Kaya, Safak] Univ Hlth Sci, Gazi Yasargil Training & Res Hosp, Clin Infect Dis & Clin Microbiol, Diyarbakir, Turkiye; [Ozguler, Muge] Univ Hlth Sci, Elazig Fethi Sekin City Hlth Practice & Res Ctr, Clin Infect Dis & Clin Microbiol, Hamidiye Fac Med, Elazig, Turkiye; [Dindar Demiray, Emine Kubra] Bitlis State Hosp, Clin Infect Dis & Clin Microbiol, Bitlis, Turkiye; [Kose, Sukran] Dokuz Eylul Univ, Fac Med, Dept Infect Dis & Clin Microbiol, Izmir, Turkiye en_US
dc.description Sarikaya, Burak/0000-0002-0026-1927 en_US
dc.description.abstract Human immunodeficiency virus (HIV)/acquired immundeficiency syndrome (AIDS) is a critical global public health problem that significantly affects both life expectancy and the overall quality of life of in dividuals in all age groups. The landscape of HIV infection has changed significantly in recent years due to the introduction of effective combination antiretroviral therapies (ART). A key component of first -line ART regimens for HIV treatment is abacavir, a nucleoside HIV reverse transcriptase inhibitor. Although ab acavir is effective in suppressing viral replication and managing disease, its clinical utility is overshadowed by the potential for life -threatening hypersensitivity reactions in HLA-B*57:01-positive patients. In our country, local data obtained from various centers regarding the prevalence of HLA-B*57:01 in HIV -1 -infected patients are available. In this study, it was aimed to determine the prevalence of the HLA-B*57:01 genotype in HIV -infected patients who were followed up and treated in many regions of our country. This retrospective study consists of the data of the patients aged 18 years and over diagnosed with HIV -1 infection between 01.01.2019 and 31.07.2022. Age, gender, place of birth, mode of transmission of the disease, death status, CD4+ T cell count and HIV RNA levels at the first clinical presentation, HLA-B*57:01 positivity, and the method used, clinical stage of the disease, virological response time with the treatment they received were recorded from the patient files. Data were collected from 16 centers and each center used different methods to detect HLA-B*57:01. These methods were sequence -specific oligonucleotide probe hybridization (SSOP), DNA sequence -based typing (SBT), single -specific primer-polymerase chain reaction (SSP-PCR), allele -specific PCR (AS-PCR) and quantitative PCR (Q-PCR). A total of 608 HIV -infected individuals, 523 males (86%) and 85 females (14%), were included in the study. The mean age of the patients was 36.9 +/- 11.9 (18-73) years. The prevalence of HLA-B*57:01 allele was found to be 3.6% (22 patients). The number of CD4+ T lymphocytes in HLA-B*57:01 allele -positive patients was > 500/ mm(3) in 10 patients (45.5%), while the number of CD4+ T lymphocytes in HLA-B*57:01 negative pa- tients was > 500/mm(3) in 216 patients (36.9%) (p> 0.05). Viral load at the time of diagnosis was found to be lower in patients with positive HLA-B*57:01 allele but it was not statistically significant (p> 0.05). Although different treatment algorithms were used in the centers following the patients, it was observed that the duration of virological response was shorter in HLA-B*57:01 positive patients (p= 0.006). Although the presence of the HLA-B*57:01 allele has a negative impact due to its association with hypersensitivity, it is likely to continue to attract interest due to its association with slower progression of HIV infection and reduced risk of developing AIDS. In addition, although the answer to the question of whether it is cost-effective to screen patients for HLA-B*57:01 before starting an abacavir-containing ART regimen for the treatment of HIV infection is being sought, it seems that HIV treatment guidelines will continue to recommend screening to identify patients at risk in this regard. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.5578/mb.20249903
dc.identifier.endpage 38 en_US
dc.identifier.issn 0374-9096
dc.identifier.issue 1 en_US
dc.identifier.pmid 38263938
dc.identifier.scopus 2-s2.0-85183460247
dc.identifier.scopusquality Q4
dc.identifier.startpage 29 en_US
dc.identifier.trdizinid 1221997
dc.identifier.uri https://doi.org/10.5578/mb.20249903
dc.identifier.uri https://hdl.handle.net/20.500.14720/15455
dc.identifier.volume 58 en_US
dc.identifier.wos WOS:001201247600006
dc.identifier.wosquality Q4
dc.language.iso en en_US
dc.publisher Ankara Microbiology Soc en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Hla-B*57 01 en_US
dc.subject Hiv en_US
dc.subject Abacavir en_US
dc.subject Prevalence en_US
dc.title Distribution of the Prevalence of Human Leukocyte Antigen (hla)-B*57:01 Positivity in Hiv-1 Infected Individuals and Its Effects on Treatment: Türkiye Map-Buhasder Working Group en_US
dc.type Article en_US

Files